Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

15:34
10/09/16
10/09
15:34
10/09/16
15:34

Merck reports long-term data from final KEYNOTE-002 analysis

Merck announced findings from the final overall survival analysis from the KEYNOTE-002 study investigating the use of Keytruda compared to investigator-choice chemotherapy with a crossover to Keytruda design, in patients with ipilimumab-refractory advanced melanoma. The results presented at the ESMO 2016 Congress include follow-up of up to 35 months for the study's co-primary endpoints of OS and progression-free survival. Data showed prolonged OS with Keytruda 2 mg/kg and 10 mg/kg, with a median OS of 13.4 months and 14.7 months and a two-year OS rate of 35.9 percent and 38.2 percent, respectively, compared to a median OS of 11.0 months and a two-year OS rate of 29.7 percent with chemotherapy. While improvements in OS between Keytruda 2 mg/kg or 10 mg/kg and chemotherapy did not meet the protocol-specified significance threshold, longer follow-up continued to show a clinically meaningful improvement in PFS, the study's co-primary endpoint, with PFS of up to 31 months in patients treated with Keytruda. Median PFS was approximately three months for each of the patient groups -- 2.8-3.8 months with Keytruda 2 mg/kg; 2.8-5.2 months with Keytruda 10 mg/kg; and 2.6-2.8 months with chemotherapy. The two-year PFS rate was 16.0 percent and 21.9 percent with Keytruda compared to 0.6 percent of patients treated with chemotherapy. ORR was 22.2 percent and 27.6 percent with Keytruda compared to 4.5 percent with chemotherapy. At the time of analysis, 50 percent and 58 percent of patients who responded to Keytruda were alive with no subsequent progression or anti-tumor therapy, compared to 12 percent of patients who responded to chemotherapy. With longer follow-up, adverse events have remained consistent with previously reported safety data.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

MS

Morgan Stanley

$55.35

0.75 (1.37%)

, BK

BNY Mellon

$57.89

0.35 (0.61%)

20:25
01/17/18
01/17
20:25
01/17/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MS

Morgan Stanley

$55.35

0.75 (1.37%)

BK

BNY Mellon

$57.89

0.35 (0.61%)

BBT

BB&T

$53.28

0.2 (0.38%)

PPG

PPG

$114.50

-2.14 (-1.83%)

MTB

M&T Bank

$179.21

1.43 (0.80%)

KEY

KeyCorp

$21.26

-0.06 (-0.28%)

JBHT

J.B. Hunt

$120.65

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 08

    Mar

  • 10

    May

ARNA

Arena Pharmaceuticals

$34.36

0.48 (1.42%)

20:24
01/17/18
01/17
20:24
01/17/18
20:24
Initiation
Arena Pharmaceuticals initiated at Credit Suisse »

Arena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROSE

Rosehill Resources

$7.96

0.01 (0.13%)

20:12
01/17/18
01/17
20:12
01/17/18
20:12
Initiation
Rosehill Resources initiated at Northland »

Rosehill Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$54.02

0.48 (0.90%)

20:10
01/17/18
01/17
20:10
01/17/18
20:10
Initiation
Hess Corp. initiated at Macquarie »

Hess Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

OXY

Occidental Petroleum

$75.86

0.59 (0.78%)

20:10
01/17/18
01/17
20:10
01/17/18
20:10
Initiation
Occidental Petroleum initiated at Macquarie »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

JUNO

Juno Therapeutics

$69.25

23.65 (51.86%)

19:53
01/17/18
01/17
19:53
01/17/18
19:53
Downgrade
Juno Therapeutics rating change at Citi »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$77.89

-0.37 (-0.47%)

19:52
01/17/18
01/17
19:52
01/17/18
19:52
Upgrade
Worldpay rating change at BMO Capital »

Worldpay upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRAC

Keane Group

$18.51

0.63 (3.52%)

19:52
01/17/18
01/17
19:52
01/17/18
19:52
Syndicate
Keane Group 13.3M share Secondary priced at $18.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

INTC

Intel

$44.39

1.25 (2.90%)

19:24
01/17/18
01/17
19:24
01/17/18
19:24
Hot Stocks
Intel says issued firmware updates for 90% of CPUs in past vie years »

Intel said it has made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

TOSBF

Toshiba, also use TOSYY

, TOSYY

Toshiba, also use TOSBF

$16.95

-0.01 (-0.06%)

19:11
01/17/18
01/17
19:11
01/17/18
19:11
Periodicals
Toshiba's Westinghouse to forgo bankruptcy, Reuters reports »

Westinghouse Electric…

TOSBF

Toshiba, also use TOSYY

TOSYY

Toshiba, also use TOSBF

$16.95

-0.01 (-0.06%)

BAM

Brookfield

$43.10

0.42 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$70.20

0.22 (0.31%)

, RDS.B

Royal Dutch Shell

$72.34

0.35 (0.49%)

19:02
01/17/18
01/17
19:02
01/17/18
19:02
Periodicals
Shell, BP each agree to purchase Libyan oil, Bloomberg reports »

Royal Dutch Shell (RDS.A)…

RDS.A

Royal Dutch Shell

$70.20

0.22 (0.31%)

RDS.B

Royal Dutch Shell

$72.34

0.35 (0.49%)

BP

BP

$42.88

0.42 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AAPL

Apple

$179.10

2.91 (1.65%)

18:31
01/17/18
01/17
18:31
01/17/18
18:31
Hot Stocks
Trump says Apple investments 'huge win for American workers' »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

MPVD

Mountain Province Diamonds

$2.83

0.075 (2.73%)

18:22
01/17/18
01/17
18:22
01/17/18
18:22
Hot Stocks
Mountain Province Diamonds provides update on Gahcho Kue Mine exploration »

Mountain Province…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAC

Walter Investment

$0.76

0.0347 (4.81%)

18:17
01/17/18
01/17
18:17
01/17/18
18:17
Hot Stocks
Walter Investment prepackaged Chapter 11 plan approved by court »

Walter Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$140.72

2.75 (1.99%)

, KBSTY

Kobe Steel

18:10
01/17/18
01/17
18:10
01/17/18
18:10
Periodicals
Toyota not affected by Kobe Steel false data scandal, Nikkei reports »

Toyota (TM) said there…

TM

Toyota

$140.72

2.75 (1.99%)

KBSTY

Kobe Steel

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

Cboe Global Markets

$131.52

0.73 (0.56%)

, BTC

Bitcoin

17:47
01/17/18
01/17
17:47
01/17/18
17:47
Hot Stocks
Cboe conducts first settlement of Cboe bitcoin futures »

Cboe Global Markets…

CBOE

Cboe Global Markets

$131.52

0.73 (0.56%)

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

GWRE

Guidewire

$75.64

0.19 (0.25%)

17:46
01/17/18
01/17
17:46
01/17/18
17:46
Hot Stocks
Guidewire director sells 6,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.10

2.91 (1.65%)

17:40
01/17/18
01/17
17:40
01/17/18
17:40
Recommendations
Apple analyst commentary at Piper Jaffray »

Apple cash repatriation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

OBE

Obsidian Energy

$1.21

-0.03 (-2.42%)

17:36
01/17/18
01/17
17:36
01/17/18
17:36
Hot Stocks
Breaking Hot Stocks news story on Obsidian Energy »

FrontFour reports 5.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SN

Sanchez Energy

$5.81

0.16 (2.83%)

17:33
01/17/18
01/17
17:33
01/17/18
17:33
Hot Stocks
Breaking Hot Stocks news story on Sanchez Energy »

Sanchez Energy sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

NTDOY

Nintendo

$51.53

1.55 (3.10%)

17:32
01/17/18
01/17
17:32
01/17/18
17:32
Hot Stocks
Nintendo announces Nintendo Labo accessories for Switch consoles »

Nintendo introduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

PTC

PTC

$66.70

1.41 (2.16%)

, ESIO

Electro Scientific

$22.01

1.91 (9.50%)

17:28
01/17/18
01/17
17:28
01/17/18
17:28
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: PTC…

PTC

PTC

$66.70

1.41 (2.16%)

ESIO

Electro Scientific

$22.01

1.91 (9.50%)

NEOT

Neothetics

$1.92

0.0793 (4.31%)

PLXS

Plexus

$64.36

0.59 (0.93%)

AA

Alcoa

$56.99

0.75 (1.33%)

SLM

Sallie Mae

$11.49

0.02 (0.17%)

ARWR

Arrowhead

$5.72

0.12 (2.14%)

PRTK

Paratek Pharmaceuticals

$17.68

-0.075 (-0.42%)

IIPR

Innovative Industrial Properties

$31.30

-2.49 (-7.37%)

ECC

Eagle Point Credit

$19.13

-0.39 (-2.00%)

AGIO

Agios Pharmaceuticals

$70.33

1.53 (2.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 07

    Feb

  • 26

    Feb

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 19

    Jan

BTU

Peabody Energy

$40.00

0.42 (1.06%)

17:17
01/17/18
01/17
17:17
01/17/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Peabody Energy »

Discovery Capital reduces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

MLNX

Mellanox

$64.30

-0.45 (-0.69%)

17:12
01/17/18
01/17
17:12
01/17/18
17:12
Hot Stocks
Starboard to nominate nine directors for election at Mellanox »

Starboard Value, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

APHB

AmpliPhi

$1.12

0.03 (2.75%)

17:11
01/17/18
01/17
17:11
01/17/18
17:11
Syndicate
AmpliPhi requests withdrawal of registration statement »

AmpliPhi confirms that no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.